Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oric Pharmaceuticals (ORIC) Cash & Equivalents (2019 - 2026)

Oric Pharmaceuticals filings provide 8 years of Cash & Equivalents readings, the most recent being $56.4 million for Q1 2026.

  • Quarterly Cash & Equivalents rose 14.31% to $56.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $56.4 million through Mar 2026, up 14.31% year-over-year, with the annual reading at $45.7 million for FY2025, 23.12% down from the prior year.
  • Cash & Equivalents hit $56.4 million in Q1 2026 for Oric Pharmaceuticals, up from $45.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $112.6 million in Q1 2022 and bottomed at $23.4 million in Q4 2023.
  • Average Cash & Equivalents over 5 years is $56.3 million, with a median of $49.8 million recorded in 2024.
  • The largest annual shift saw Cash & Equivalents plummeted 87.94% in 2022 before it soared 154.05% in 2024.
  • Oric Pharmaceuticals' Cash & Equivalents stood at $66.8 million in 2022, then tumbled by 65.01% to $23.4 million in 2023, then soared by 154.05% to $59.4 million in 2024, then dropped by 23.12% to $45.7 million in 2025, then grew by 23.49% to $56.4 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Cash & Equivalents are $56.4 million (Q1 2026), $45.7 million (Q4 2025), and $49.7 million (Q3 2025).